Stentys (http://www.stentys.com) announced today that its bifurcated stent was successfully implanted recently into a 49-year-old male patient at the ThoraxCenter, Erasmus Medical Center, Rotterdam, the Netherlands. This case is the sixth successful implantation of the Stetys bifurcated stent platform.
PARIS (Business Wire EON) January 31, 2008 --
Stentys
(http://www.stentys.com) announced
today that its bifurcated
stent was successfully implanted recently into a 49-year-old male
patient at the ThoraxCenter, Erasmus Medical Center, Rotterdam, the
Netherlands. This case is the sixth
successful implantation of the Stetys bifurcated stent platform.
Stentys has developed the
world’s first next-generation dedicated
drug-eluting stent for treatment of blocked coronary artery
bifurcations that is designed so that hundreds of thousands of patients
might avoid open-chest surgery. This sixth case, similar to the five
previous cases, took routine interventional time to complete; the
patient was released from the ICU within hours of the implantation of
the Stentys bifurcated
stent and was discharged from the hospital shortly after the
procedure.
“This sixth consecutive clinical achievement
underscores our conviction that the Stentys bifurcated stent will enable
interventional cardiologists to offer their patients the next
generation of dedicated bifurcated-stenting procedures,”
said Stentys’ CEO and co-founder, Gonzague
Issenmann.
“The fact that the Stentys procedure is
identical to the current standard techniques while allowing more
treatment options with side-branch access suggests that this platform
has the potential to offer a practical alternative to conventional
stenting procedures in treating blocked coronary artery bifurcations,”
said Dr. Patrick Serruys, who is head of Erasmus Medical Center’s
department of interventional cardiology and a member of the Stentys
scientific advisory board.
Coronary artery disease is caused by fatty lesions that narrow the
coronary artery’s inside diameter (stenosis),
consequently reducing the blood flow and depriving the heart muscle of
oxygen. The dramatic consequence of this blockage is an often-lethal
myocardial infarction (heart attack). Bifurcation is the area where one
main vessel branches out into two smaller vessels, one being the
continuation of the main vessel, and the other often referred to as the
side branch. Narrowings at a bifurcation site are quite common. Indeed,
18 percent of percutaneous coronary interventions involve a bifurcation
stenosis. Of those, restenosis (re-occurrence of the blockage) occurs in
20-25 percent of bifurcations treated with drug-eluting stents (DES).
The patent-pending innovation of Stentys’
bifurcated stent is that the stent-opening for the side branch can be
created anywhere in the stent after it is implanted in the vessel. In
short, the procedure’s success is independent
from accurate positioning. The Stentys procedure is performed in three
simple steps: (1) Stentys is implanted in the main vessel with an
approximate positioning, like a standard stent; (2) the cardiologist
chooses the optimal location for the side branch opening by inserting a
balloon through the stent mesh, which is a cath lab-standard procedure;
and, (3) the balloon inflation disconnects the mesh and creates the
opening—Stentys’
self-expanding property allows the in situ modeling of the stent to fit
the patient’s unique arterial anatomy.
Based in Paris, Stentys intends to make treatment of blocked coronary
artery bifurcations as simple and effective as a conventional stenting
procedure.
Trackback URL: http://www.prweb.com/pingpr.php/SW5zZS1Qcm9mLUhhbGYtUGlnZy1aZXRhLVplcm8=
|
